Results 81 to 90 of about 8,536,940 (156)

Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry

Pediatric Dermatology, EarlyView.
ABSTRACT Background/Objective The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population.
Amy S. Paller, Alan D. Irvine, Eulalia Baselga, Marlies de Graaf, Elaine C. Siegfried, Michael J. Cork, Michele Ramien, Lawrence F. Eichenfield, Bryan Adams, Rajan Gupta, Marius Ardeleanu, Annie Zhang   +11 more
wiley   +1 more source

Australian Pharmacy Law and Practice [PDF]

, 2013
[Extract] Fully revised and updated, this new edition of Australian Pharmacy Law and Practice provides an indispensable introduction for both students and professionals seeking to enhance their knowledge of the law in the ever-changing area of pharmacy ...
Forrester, Kim, Low, John, Hattingh, Laetitia   +2 more
core   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Good pharmacy practice assessment among community pharmacies in Lebanon

, 2020
Objective: This study aims to assess good pharmacy practice (GPP) aspects and compare GPP scores among community pharmacies in Lebanon, using a tool developed jointly by the International Pharmaceutical Federation (FIP) and the World Health Organization (
Sacre,Hala, Salameh,Pascale, Hallit,Souheil, Amhaz,Ali, Badro,Danielle A   +4 more
core   +2 more sources

Optimizing Nurse‐Involved Non‐Pharmacological Interventions for Postoperative Pain: A Scoping Review

Journal of Clinical Nursing, Volume 35, Issue 11, Page 4629-4647, November 2026.
ABSTRACT Aim To identify the types of non‐pharmacological interventions, nurses' roles and outcome measures used for postoperative pain management in inpatients. Design A scoping review was conducted following the Joanna Briggs Institute guidelines. Methods Eligible studies were those involving adult surgical inpatients receiving nurse‐involved non ...
Jihyung Son, Sunghwa Na, Hyun Joo Lee
wiley   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Savolitinib is an oral, potent, selective CNS‐penetrant MET‐tyrosine kinase inhibitor that in vitro studies indicate is metabolized by cytochrome P450 (CYP) enzymes, including CYP1A2, and by non‐CYP enzymes, such as aldehyde oxidase (AO). Savolitinib primary metabolites, M2 and M3, are formed mainly by CYP1A2 and AO, respectively. This Phase 1,
Kowser Miah, Jitendar Reddy, Pradeep Sharma, Ike Igwegbe, Simon Nelson, Caitlin Muldoon, Ronald Goldwater, Karthick Vishwanathan   +7 more
wiley   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8946-8954, October 2026.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source